Continuous glucose monitoring (CGM) has revolutionized diabetes management, transforming both clinical practice and the self-management of people with diabetes. By providing a more detailed understanding of individual glycemic patterns, CGM supports more informed therapeutic decisions and sustained behavioral changes that promote improved clinical outcomes and quality of life. In light of new evidence and accumulated experience, it has become necessary to update the clinical indications and public health strategy for the use of CGM in Portugal. The recommendations focused on three priority areas: (1) the clear definition of target populations for CGM use, namely all individuals with diabetes treated with any insulin regimen (including basal therapy), as well as those not treated with insulin but at increased risk of hypoglycemia and its consequences, based on eligibility criteria grounded in scientific evidence and clinical needs; (2) the strengthening of therapeutic education and health literacy, promoted by multidisciplinary teams trained to support self-management and the appropriate use of technology; and (3) ensuring the quality and integrated functioning of CGM systems with other medical devices, including insulin pumps and digital monitoring platforms, in order to guarantee interoperability, reliability, and data management security.
Neves et al. (2026) studied this question.